Search results
We’re on the road with a new approach to clinical trials—one that expands access to cutting-edge medicines and treatments. Lilly is a medicine company turning science into healing to make life better for people around the world.
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Our Commitment to Making Life Better. Home page for Eli Lilly and Company in Canada.
We’re a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
Nov 8, 2023 · Lilly is putting a commercial savings card program in place that will help people who may benefit from Zepbound better access it. People who are commercially insured with coverage for Zepbound may be eligible to pay as low as $25 for a 1-month or 3-month prescription.
Find your place at Lilly with Lilly Careers. For more than a century, we have united caring with discovery to make life better, join us today.
4 days ago · Eli Lilly and Novo Nordisk are racing to increase production in a weight-loss market estimated to reach at least $100 billion globally by the end of the decade. Both companies' obesity treatments ...
Dec 15, 2021 · INDIANAPOLIS, Dec. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is providing extensive updates across its research and development (R&D) programs to highlight the company's strong pipeline and potential for future growth. At an investment community meeting today, the company is sharing key information across its four therapeutic ...
6 days ago · Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche’s latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight ...
Aug 8, 2023 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
